17,261 trials
AIDS-Related Plasmablastic Lymphoma · AIDS-Related Primary Effusion Lymphoma · Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
Primary: Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) — 67.5; 76.2 percentage of participants
Pneumonia, Pneumococcal
Primary: Number/Percent of Adult Subjects Experiencing Fatigue/Malaise Following Vaccination — 15; 15; 18; 16 Participants
HIV/AIDS-associated Fatigue
Primary: Change in Fatigue Severity Score (FSS) — -24.7; -16.3; -16.9; -21.6 units on a scale — p=0.15
Sarcopenia
Primary: Change From Baseline in Isokinetic Strength — -4.90; -4.73 Newton — p=0.97
Lymphoma
Primary: Overall Response Rate (ORR) as Determined by IRRC — 4.3 Percentage of participants
Jansky-Bielschowsky Disease · Batten Disease · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Primary: Motor-Language (ML) Scale Score During 300 mg Dosing Period — 3.5; 3.1; -0.4 units on a scale — p=0.0002
Pompe Disease
Primary: Number of Participants With Adverse Events — 3; 3; 15 Participants
Major Depressive Disorder · Treatment Resistant
Primary: Montgomery-Asberg Depression Rating Scale — -13.0 change in units on a scale
Chronic Pain · Post-operative Pain
Primary: Time to Pain Resolution — 17; 15 DAYS
Nonconvulsive Seizures
Primary: Percentage of Subjects Who Experience no Nonconvulsive Seizures (NCS) for 24 Hours Following Treatment With LCM vs. fPHT, as Measured by Continuous…
Diabetes Mellitus, Type 2
Primary: Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles — 6.83; 7.15; 6.84 millimoles per Liter…
Melanoma
Primary: Objective Response Rate (ORR) — 22 percentage of patients
Influenza
Primary: Number of Participants With Any Solicited Influenza Symptoms From Day 1 Through Day 10 — 32; 31; 31; 31 Participants
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Non Squamous Non Small Cell Lung Cancer
Primary: Median Progression-Free Survival — 6; 4.9 months